Unknown

Dataset Information

0

Emerging therapies for breast cancer.

ABSTRACT: HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.

SUBMITTER: Hu X 

PROVIDER: S-EPMC5410098 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Emerging therapies for breast cancer.

Hu Xichun X   Huang Wei W   Fan Minhao M  

Journal of hematology & oncology 20170428 1

HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy  ...[more]

Similar Datasets

Unknown Treating breast cancer in the 21st century: emerging biological therapies.
| S-EPMC3563073 | biostudies-other
Unknown Emerging therapies in pancreas cancer.
| S-EPMC3397600 | biostudies-other
Unknown Emerging Therapies in Penile Cancer.
| S-EPMC9253417 | biostudies-literature
Unknown Emerging Cellular Therapies for Cancer.
| S-EPMC7399614 | biostudies-literature
Unknown Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer.
| S-EPMC6492227 | biostudies-literature
Unknown Emerging Systemic Therapies for Colorectal Cancer.
| S-EPMC5929883 | biostudies-literature
Unknown Emerging therapies for small cell lung cancer.
| S-EPMC6498593 | biostudies-literature
Unknown Emerging Therapies.
| S-EPMC5823282 | biostudies-literature
Unknown Emerging targeted therapies for castration-resistant prostate cancer.
| S-EPMC3364443 | biostudies-literature
Unknown New and emerging combination therapies for esophageal cancer.
| S-EPMC3706320 | biostudies-literature